Announcements Trials
Browse Landscape

Phase

Phase 2 16Phase 1 3Phase 3 2Phase 2/3 2Phase 1/2 2

Status

Not yet recruiting 2Completed 2Withdrawn 1Unknown 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Pancreatic Neoplasms 1Neoplasm Metastasis 1Esophageal Neoplasms 1Adenocarcinoma 1

Interventions

Cisplatin 22Fluorouracil 21Radiotherapy 18Gemcitabine 17Docetaxel 16Oxaliplatin 15Paclitaxel 14Carboplatin 13Capecitabine 13Bevacizumab 13Leucovorin 11Cyclophosphamide 11Irinotecan 10Drug Therapy 10Cytarabine 9Saline Solution 7Magnetic Resonance Spectroscopy 7Letrozole 7Dexamethasone 7Rituximab 6Nivolumab 6Methotrexate 6Exercise 6Etoposide 6Electroporation 6Doxorubicin 6pembrolizumab 5Pemetrexed 5Metformin 5Melphalan 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Completed × nimotuzumab × Clear all
NCT01249352 2025-03-31

NICE

Eurofarma Laboratorios S.A.

Phase 2/3 Completed
104 enrolled
Gastrointestinal

Adenocarcinoma, Esophageal Neoplasms

NCT00561990 2015-10-15

Nimotuzumab in Adults With Pancreatic Cancer

Oncoscience AG

Phase 2/3 Completed
188 enrolled
Gastrointestinal

Neoplasm Metastasis, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡